Table 1.
Clinical characteristics comparing patients in the early era to the modern era.
| All patients (N=187) | Early Era (N=89) | Modern Era (N=93) | P Value | |
|---|---|---|---|---|
| Age (years, mn±SD) | 45 ± 17 | 43 ± 18 | 48 ± 13 | 0.03 |
| African American (%) | 39% | 26% | 54% | 0.02 |
| Non-ischemic (%) | 67% | 62% | 72% | 0.13 |
| Female (%) | 26% | 31% | 23% | 0.19 |
| Female Donor (%) | 32% | 42% | 24% | 0.009 |
| Ischemic Time (min, mean ± SD) | 182 ± 60 | 162 ± 52 | 201 ± 53 | <0.001 |
| Maintenance Therapy | < 0.001 | |||
| CS + AZA (%) | 47% | 92% | 4% | |
| TAC + AZA (%) | 10% | 5% | 16% | |
| TAC + MMF (%) | 42% | 3% | 80% | |
| Induction Therapy | 59% | 44% | 80% | <0.001 |
| ATG (%) | 41% | 29% | 58% | |
| IL2-inhibitor (%) | 11% | 0% | 22% | |
| OKT3 (%) | 7% | 15% | 0% | |
| MCS (%) | 40% | 11% | 69% | <0.001 |
| Donor-Recipient Race | 47% | 38% | 55% | 0.03 |
| Mismatch (%) | ||||
| CMV Status | 0.3 | |||
| Donor − / Recipient − | 23% | 27% | 24% | |
| Donor + / Recipient + | 47% | 59% | 50% | |
| Donor − / Recipient + | 11% | 10% | 14% | |
| Donor + / Recipient − | 7% | 4% | 11% | |
ATG = anti-thymocyte globulin; CMV = cytomegalovirus; IL2 = interleukin 2; MCS = mechanical circulatory support; OKT3 = muromonab-CD3; SD = standard deviation.